Infigratinib Shows Broad Benefits in Achondroplasia: Sleep Apnea, Ear Infections, and 3-Year Growth Data
BBIO sits 52% above its 52-week low of $48.78.
Summary
BridgeBio presented new exploratory data from the Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia at ESPE 2026. The drug stabilized sleep apnea measures (AHI +10.4% vs +49.2% placebo) and reduced ear infections by 38% versus placebo. Three-year data showed sustained growth improvements (height Z-score +0.92 SD) with no new safety signals. The company has submitted an NDA to the FDA and expects a U.S. launch in mid-2027, with an MAA filing to EMA planned for Q4 2026. This broadens the drug's profile beyond the previously reported primary endpoint of annualized height velocity, strengthening its commercial positioning as a potential first oral therapy for achondroplasia.
At the time of this announcement, BBIO was trading at $74.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.6B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.